|
|
|
|
| LEADER |
02005nam a2200253 u 4500 |
| 001 |
EB002010764 |
| 003 |
EBX01000000000000001173663 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 100 |
1 |
|
|a Li, Ke Xin
|
| 245 |
0 |
0 |
|a Second-line therapy for patients with relapsing-remitting multiple sclerosis
|h Elektronische Ressource
|b a review of guidelines
|c authors, Ke Xin Li, Lory Picheca
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2019, September 26, 2019
|
| 300 |
|
|
|a 1 PDF file (15 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Picheca, Lory
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK549531
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a There is uncertainty in clinical practice regarding how and when to switch from the first-line therapy to a second-line therapy for relapsing-remitting multiple sclerosis (RRMS). This review seeks to report on the critically appraisal of the evidence-based guidelines regarding switching to a second-line therapy in patients with RRMS. One evidence-based guideline was identified with one strong recommendation regarding switching from an interferon or glatiramer acetate to a second-line therapy in patients with relapsing-remitting multiple sclerosis and evidence of disease activity. Consensus statements provided by the guideline suggest that there is insufficient evidence on patient factors or disease activity considerations to make more specific recommendations for switching to second-line treatments. The consensus statements presented in this report should be interpreted with caution based on the limitations and paucity of evidence
|